Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (292) 292
Publication (28) 28
Patent (15) 15
Book / eBook (2) 2
Book Chapter (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (107) 107
index medicus (88) 88
oncology (82) 82
melanoma (77) 77
female (72) 72
male (60) 60
middle aged (53) 53
aged (52) 52
cancer (48) 48
melanoma - drug therapy (48) 48
adult (47) 47
immunotherapy (40) 40
melanoma - pathology (32) 32
metastatic melanoma (32) 32
treatment outcome (30) 30
aged, 80 and over (28) 28
ipilimumab (27) 27
animals (25) 25
skin neoplasms - drug therapy (25) 25
tumors (25) 25
antineoplastic combined chemotherapy protocols - therapeutic use (24) 24
care and treatment (22) 22
chemotherapy (22) 22
antineoplastic agents - therapeutic use (21) 21
mutation (21) 21
safety (21) 21
skin neoplasms - pathology (21) 21
survival (21) 21
melanoma - therapy (20) 20
pembrolizumab (20) 20
nivolumab (19) 19
melanoma - immunology (17) 17
young adult (17) 17
neoplasm staging (16) 16
neoplasms - drug therapy (16) 16
chemistry (15) 15
metallurgy (15) 15
metastasis (15) 15
pd-1 (15) 15
research (15) 15
antineoplastic agents - adverse effects (14) 14
article (14) 14
clinical trials (14) 14
disease-free survival (14) 14
radiation therapy (14) 14
therapy (14) 14
anti-pd-1 (13) 13
antibodies, monoclonal - therapeutic use (13) 13
antibodies, monoclonal, humanized - therapeutic use (13) 13
antineoplastic agents - administration & dosage (13) 13
drug administration schedule (13) 13
expression (13) 13
melanoma - genetics (13) 13
patients (13) 13
prognosis (13) 13
programmed cell death 1 receptor - antagonists & inhibitors (13) 13
proto-oncogene proteins b-raf - genetics (13) 13
abridged index medicus (12) 12
adolescent (12) 12
apoptosis (12) 12
biochemistry (12) 12
disease progression (12) 12
human necessities (12) 12
hygiene (12) 12
immunology (12) 12
immunotherapy - methods (12) 12
medical or veterinary science (12) 12
preparations for medical, dental, or toilet purposes (12) 12
analysis (11) 11
beer (11) 11
dermatology (11) 11
electrotherapy (11) 11
enzymology (11) 11
magnetotherapy (11) 11
melanoma - mortality (11) 11
mice (11) 11
microbiology (11) 11
mutation or genetic engineering (11) 11
peptides (11) 11
programmed cell death 1 receptor - immunology (11) 11
skin cancer (11) 11
skin neoplasms - therapy (11) 11
spirits (11) 11
ultrasound therapy (11) 11
vinegar (11) 11
wine (11) 11
antigens (10) 10
blockade (10) 10
cell biology (10) 10
organic chemistry (10) 10
proto-oncogene proteins b-raf - antagonists & inhibitors (10) 10
responses (10) 10
survival rate (10) 10
antibodies, monoclonal - administration & dosage (9) 9
antibodies, monoclonal, humanized - administration & dosage (9) 9
biopsy (9) 9
health aspects (9) 9
improved survival (9) 9
malignant-melanoma (9) 9
melanoma - diagnosis (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Response to PD-1 inhibition in early- and late-relapsing cutaneous melanoma
by Fitzgerald, Kelly and Daud, Adil
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e21038 - e21038
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
by Robert, Caroline, Prof and Ribas, Antoni, Prof and Wolchok, Jedd D, Prof and Hodi, F Stephen, MD and Hamid, Omid, MD and Kefford, Richard, Prof and Weber, Jeffrey S, Prof and Joshua, Anthony M, PhD and Hwu, Wen-Jen, Prof and Gangadhar, Tara C, MD and Patnaik, Amita, MD and Dronca, Roxana, MD and Zarour, Hassane, Prof and Joseph, Richard W, MD and Boasberg, Peter, MD and Chmielowski, Bartosz, MD and Mateus, Christine, MD and Postow, Michael A, MD and Gergich, Kevin, MA and Elassaiss-Schaap, Jeroen, PhD and Li, Xiaoyun Nicole, PhD and Iannone, Robert, MD and Ebbinghaus, Scot W, MD and Kang, S Peter, MD and Daud, Adil, Prof
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9948, pp. 1109 - 1117
Summary Background The anti-programmed-death-receptor-1 (PD-1) antibody pembrolizumab has shown potent antitumour activity at different doses and schedules in... 
Internal Medicine | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | RESPONSE CRITERIA | MEK INHIBITION | SAFETY | IMMUNOTHERAPY | MUTATION | BRAF INHIBITORS | IMPROVED SURVIVAL | OPEN-LABEL | PD-1 | Drug Eruptions - etiology | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Antibodies, Monoclonal, Humanized | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Melanoma - drug therapy | Adolescent | Adult | Female | Aged | Pruritus - chemically induced | Dose-response relationship (Biochemistry) | Pharmacology, Experimental | Research | Drug therapy | Melanoma | Antigens | Cytotoxicity | Metastasis | Kinases | Drug dosages | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Current and Emerging Perspectives on Immunotherapy for Melanoma
by Daud, Adil
Seminars in Oncology, ISSN 0093-7754, 12/2015, Volume 42, Issue 6, pp. S3 - S11
Novel immunotherapeutic treatments are aimed at reversing the action of inhibitory pathways that restrain the T-cell dominated immune-mediated defense against... 
COLONY-STIMULATING FACTOR | ONCOLOGY | SAFETY | PEMBROLIZUMAB PEMBRO | CTLA-4 | PATIENTS PTS | NIVOLUMAB | CANCER | PD-1 | IPILIMUMAB | CHECKPOINT BLOCKADE | Immunotherapy - methods | Signal Transduction | Melanoma - immunology | Humans | Melanoma - drug therapy | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Combined Modality Therapy | CTLA-4 Antigen - antagonists & inhibitors | Immunotherapy - adverse effects | Index Medicus
Journal Article
Details down arrow
4. Full Text Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
by Ribas, Antoni, Prof and Puzanov, Igor, MD and Dummer, Reinhard, Prof and Schadendorf, Dirk, Prof and Hamid, Omid, MD and Robert, Caroline, Prof and Hodi, F Stephen, MD and Schachter, Jacob, Prof and Pavlick, Anna C, MD and Lewis, Karl D, MD and Cranmer, Lee D, MD and Blank, Christian U, MD and O'Day, Steven J, MD and Ascierto, Paolo A, Prof and Salama, April K S, MD and Margolin, Kim A, Prof and Loquai, Carmen, MD and Eigentler, Thomas K, MD and Gangadhar, Tara C, MD and Carlino, Matteo S, MBBS and Agarwala, Sanjiv S, Prof and Moschos, Stergios J, MD and Sosman, Jeffrey A, Prof and Goldinger, Simone M, MD and Shapira-Frommer, Ronnie, MD and Gonzalez, Rene, Prof and Kirkwood, John M, Prof and Wolchok, Jedd D, Prof and Eggermont, Alexander, Prof and Li, Xiaoyun Nicole, PhD and Zhou, Wei, PhD and Zernhelt, Adriane M, BS and Lis, Joy, BSN and Ebbinghaus, Scot, MD and Kang, S Peter, MD and Daud, Adil, Prof
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Summary Background Patients with melanoma that progresses on ipilimumab and, if BRAFV600 mutant-positive, a BRAF or MEK inhibitor or both, have few treatment... 
Hematology, Oncology and Palliative Medicine | IMMUNE | RESPONSES | ANTI-PD-L1 ANTIBODY | ONCOLOGY | SAFETY | PD-1 BLOCKADE | BROADENS | NIVOLUMAB | MPDL3280A | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antineoplastic Agents - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Skin Neoplasms - immunology | Kaplan-Meier Estimate | Treatment Outcome | Melanoma - pathology | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - immunology | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Aged | Melanoma - mortality | Chemotherapy | Hospitals | Melanoma | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Negative but not futile: MAGE-A3 immunotherapeutic for melanoma
by Daud, Adil I
The Lancet Oncology, ISSN 1470-2045, 07/2018, Volume 19, Issue 7, pp. 852 - 853
METASTATIC MELANOMA | IMMUNIZATION | PROTEIN | ONCOLOGY | CELL
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Revisiting RECIST: the case of treatment beyond progression
by Daud, Adil I
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 157 - 159
CRITERIA | ONCOLOGY | Programmed Cell Death 1 Receptor | Response Evaluation Criteria in Solid Tumors | Humans | Disease Progression | United States Food and Drug Administration | Melanoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Introduction
by Daud, Adil I
Seminars in Cutaneous Medicine and Surgery, ISSN 1085-5629, 06/2018, Volume 37, Issue 2, p. 87
Journal Article
Details down arrow
8. Full Text Pembrolizumab versus Ipilimumab in Advanced Melanoma
by Robert, Caroline and Schachter, Jacob and Long, Georgina V and Arance, Ana and Grob, Jean Jacques and Mortier, Laurent and Daud, Adil and Carlino, Matteo S and McNeil, Catriona and Lotem, Michal and Larkin, James and Lorigan, Paul and Neyns, Bart and Blank, Christian U and Hamid, Omid and Mateus, Christine and Shapira-Frommer, Ronnie and Kosh, Michele and Zhou, Honghong and Ibrahim, Nageatte and Ebbinghaus, Scot and Ribas, Antoni and KEYNOTE-006 Investigators and KEYNOTE-006 investigators
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 26, pp. 2521 - 2532
In a multinational, randomized study, pembrolizumab produced significantly improved progression-free and overall survival and less high-grade toxicity than did... 
SURVIVAL | CRITERIA | RESPONSES | MEDICINE, GENERAL & INTERNAL | LIGANDS | SAFETY | IMMUNOTHERAPY | PD-1 BLOCKADE | MUTATION | TUMOR | NIVOLUMAB | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Young Adult | Antineoplastic Agents - adverse effects | Skin Neoplasms - mortality | Melanoma - drug therapy | Adolescent | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Programmed Cell Death 1 Receptor - immunology | Melanoma - mortality | Prognosis | Melanoma | Dosage and administration | Research | Comparative analysis | Drug therapy | PD-1 protein | Toxicity | Body weight | Patients | Pembrolizumab | Chemotherapy | Immune checkpoint | Cell death | Immunotherapy | Antitumor activity | Mutation | Apoptosis | Immune system | Fees & charges | Laboratories | Equity | Equity stake | Response rates | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
by Schachter, Jacob and Ribas, Antoni and Long, Georgina V and Arance, Ana and Grob, Jean-Jacques and Mortier, Laurent and Daud, Adil and Carlino, Matteo S and McNeil, Catriona and Lotem, Michal and Larkin, James and Lorigan, Paul and Neyns, Bart and Blank, Christian and Petrella, Teresa M and Hamid, Omid and Zhou, Honghong and Ebbinghaus, Scot and Ibrahim, Nageatte and Robert, Caroline
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10105, pp. 1853 - 1862
Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with... 
MEDICINE, GENERAL & INTERNAL | MONOTHERAPY | TOXICITIES | MANAGEMENT | COMBINED NIVOLUMAB | ANTI-PD-1 | BLOCKADE | Pharmaceutical industry | Analysis | Immunoglobulins | Immune response | Melanoma | Clinical trials | Oncology | Lymphocytes T | Metastasis | FDA approval | Patients | Survival | Studies | Immune checkpoint | Immunotherapy | Cancer | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
by Hamid, Omid and Robert, Caroline and Daud, Adil and Hodi, F. Stephen and Hwu, Wen-Jen and Kefford, Richard and Wolchok, Jedd D and Hersey, Peter and Joseph, Richard W and Weber, Jeffrey S and Dronca, Roxana and Gangadhar, Tara C and Patnaik, Amita and Zarour, Hassane and Joshua, Anthony M and Gergich, Kevin and Elassaiss-Schaap, Jeroen and Algazi, Alain and Mateus, Christine and Boasberg, Peter and Tumeh, Paul C and Chmielowski, Bartosz and Ebbinghaus, Scot W and Li, Xiaoyun Nicole and Kang, S. Peter and Ribas, Antoni
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 134 - 144
Antibodies to PD-1 appeared to unblock T-cell responses to melanoma in a sizeable fraction of patients with antitumor responses, some of which were... 
CRITERIA | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | PHASE | THERAPY | IMMUNOTHERAPY | ANTIBODY | BLOCKADE | CANCER | PD-1 | Skin Neoplasms - pathology | Skin Neoplasms - drug therapy | Drug Administration Schedule | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - pharmacokinetics | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - administration & dosage | Melanoma - secondary | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Brain Neoplasms - secondary | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Melanoma - drug therapy | Aged, 80 and over | Adult | Female | Aged | Antineoplastic Agents - pharmacokinetics | Antimitotic agents | Clinical trials | Research | Drug therapy | Antineoplastic agents | Melanoma | Immune response | PD-1 protein | Body weight | Diarrhea | Cytotoxicity | Fatigue | Lymphocytes T | Pruritus | Patients | Pembrolizumab | Immune checkpoint | Lymphocytes | Ligands | Solid tumors | Apoptosis | Immune system | Tumors | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
by Ribas, Antoni and Hamid, Omid and Daud, Adil and Hodi, F. Stephen and Wolchok, Jedd D and Kefford, Richard and Joshua, Anthony M and Patnaik, Amita and Hwu, Wen-Jen and Weber, Jeffrey S and Gangadhar, Tara C and Hersey, Peter and Dronca, Roxana and Joseph, Richard W and Zarour, Hassane and Chmielowski, Bartosz and Lawrence, Donald P and Algazi, Alain and Rizvi, Naiyer A and Hoffner, Brianna and Mateus, Christine and Gergich, Kevin and Lindia, Jill A and Giannotti, Maxine and Li, Xiaoyun Nicole and Ebbinghaus, Scot and Kang, S. Peter and Robert, Caroline
JAMA, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1600 - 1609
IMPORTANCE: The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody... 
MEDICINE, GENERAL & INTERNAL | SAFETY | IPILIMUMAB | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Young Adult | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Survival Rate | Treatment Outcome | Melanoma - pathology | Disease Progression | Disease-Free Survival | Algorithms | Melanoma - drug therapy | Aged | Melanoma - mortality | Clinical trials | Usage | Care and treatment | Melanoma | Immunoglobulins | Drug therapy | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. A review of novel intralesional therapies for melanoma, with an emphasis on a potential combination approach
by Chen, Lawrence and Daud, Adil
ONCOLOGY (United States), ISSN 0890-9091, 05/2016, Volume 30, Issue 5, pp. 442 - 443
Oncolytic Virotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Skin Neoplasms - therapy | Humans | Genetic Therapy - methods
Journal Article
Details down arrow
13. Full Text PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
by Nghiem, Paul T and Bhatia, Shailender and Lipson, Evan J and Kudchadkar, Ragini R and Miller, Natalie J and Annamalai, Lakshmanan and Berry, Sneha and Chartash, Elliot K and Daud, Adil and Fling, Steven P and Friedlander, Philip A and Kluger, Harriet M and Kohrt, Holbrook E and Lundgren, Lisa and Margolin, Kim and Mitchell, Alan and Olencki, Thomas and Pardoll, Drew M and Reddy, Sunil A and Shantha, Erica M and Sharfman, William H and Sharon, Elad and Shemanski, Lynn R and Shinohara, Michi M and Sunshine, Joel C and Taube, Janis M and Thompson, John A and Townson, Steven M and Yearley, Jennifer H and Topalian, Suzanne L and Cheever, Martin A
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 26, pp. 2542 - 2552
Merkel-cell carcinoma is an aggressive neuroendocrine tumor that is poorly responsive to chemotherapy. In a small series of patients, pembrolizumab produced... 
CRITERIA | RESPONSES | MEDICINE, GENERAL & INTERNAL | POLYOMAVIRUS | SAFETY | ANTI-PD-1 | NIVOLUMAB | EXPRESSION | CANCER | TUMORS | CHEMOTHERAPY | Skin Neoplasms - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Recurrence | Skin Neoplasms - drug therapy | Drug Administration Schedule | Humans | Middle Aged | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - administration & dosage | Carcinoma, Merkel Cell - drug therapy | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aged | Neoplasm Staging | Carcinoma, Merkel Cell - pathology | Clinical trials | Care and treatment | Usage | Diagnosis | Merkel cell carcinoma | Antigens | PD-1 protein | U.V. radiation | Body weight | Lymphocytes T | Cancer therapies | Patients | Skin cancer | Pembrolizumab | Chemotherapy | Medical prognosis | PD-L1 protein | Solid tumors | Apoptosis | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights